• Eli Lilly, the US drugmaker, said it is partnering with the Bill & Melinda Gates Foundation to supply its COVID-19 antibody therapy to low- and middle-income countries.
  • The announcement came moments before US President Donald Trump said he would approve Eli Lilly’s antibody treatment in the US.
  • Eli Lilly is seeking an emergency use authorization from the Food and Drug Administration (FDA).
  • The company said that it would aim to distribute the therapy to low-income countries before April 2021, depending on when the drug was approved in different nations.
  • Visit Business Insider’s homepage for more stories.

Drugmaker Eli Lilly has announced that it has partnered with the Bill & Melinda Gates Foundation to supply its COVID-19 antibody therapy to low- and middle-income countries.

The agreement is part of the COVID-19 Therapeutics Accelerator, an initiative launched by the Gates Foundation, Mastercard, and Wellcome to accelerate the development of and access to

Read More

BEIJING, Sept. 27, 2020 /PRNewswire/ — Companies from over 100 countries demonstrated their support for the Statement from Business Leaders for Renewed Global Cooperation presented to UN Secretary – General Antonio Guterres by Sanda Ojiambo, the CEO & Executive Director of the UN Global Compact on September 21, 2020 to mark the UN’s 75th anniversary.

Pan Gang, Chairman and President of Yili Group
Pan Gang, Chairman and President of Yili Group

As the invited representative of food industry entrepreneurs, chairman and president of global healthy food producer Yili Group Pan Gang signed the statement together with over 200 CEOs of major global companies, including Alex Gorsky, CEO of Johnson & Johnson, Brad Smith, President of Microsoft, and Punit Renjen, Global CEO of Deloitte Global, to express his support for the United Nations’ call to jointly lead the world onto a more equitable, inclusive and sustainable path of development and to “unite in the

Read More

Wealthy nations have already secured over 50 per cent of the promised doses of potential Covid-19 vaccine, according to a report by Oxfam.

“Wealthy nations representing just 13 per cent of the world’s population have already cornered more than half (51 per cent) of the promised doses of leading Covid-19 vaccine candidates,” the report said.

The report is based on the analysis of the deals that pharmaceutical corporations and vaccine producers have struck so far with nations around the world for the five leading vaccine candidates currently in phase 3 clinical trials. This includes Gamaleya/Sputnik, Pfizer, AstraZeneca, Moderna and Sinovac.

The analysis is based on data collected by Airfinity. According to Oxfam’s calculations, the combined production capacity of these five vaccine candidates stands at 5.94 billion doses. This is enough for 2.97 billion people, provided all of these vaccines require two doses.

“Supply deals have already been agreed for 5.303

Read More

The OECD said the combined GDP of its members fell by 9.8% in the second quarter of 2020. Photo: Mike Kemp/In PIctures via Getty Images
The OECD said the combined GDP of its members fell by 9.8% in the second quarter of 2020. Photo: Mike Kemp/In PIctures via Getty Images

The economic damage done to developed nations by the COVID-19 crisis has far eclipsed the damage done by the financial crisis, the Organisation for Economic Co-operation and Development (OECD) said on Wednesday.

The OECD, which represents 37 developed nations around the world, said the combined GDP of its members fell by 9.8% in the second quarter of 2020.

The second quarter collapse in GDP was “unprecedented,” the OECD said, and “significantly larger” than the 2.3% decline seen in the first quarter of 2009, which marked the worst three month period of the financial crisis.

The OECD and its partners represent 80% of global trade and investment, according to the organisation, underlining the importance of its figures.

The organisation said the huge second quarter GDP slump

Read More